Skip to content

Study on the antihypertensive effect of supplementation

Study on the antihypertensive effect of supplementation - Study on the antihypertensive effect of supplementation

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000053393
Enrollment
60
Registered
2024-01-19
Start date
2024-01-23
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Adults

Interventions

Take 3 tablets of the supplement with water before dinner every day for 12 weeks. Take 3 tablets of the placebo food with water before dinner every day for 12 weeks.

Sponsors

Healthcare Systems Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1.Persons who received a sufficient explanation of the purpose and contents of the exam, have the capacity to consent, applied with free will with sufficient understanding, and agreed to participate with a written document 2.Japanese persons who are 18 years old or more and under 65 years old

Exclusion criteria

Exclusion criteria: 1.Persons who have chronic illness, receiving medication, have a serious disease history 2.Persons who have been diagnosed with hypertension by a doctor 3.Persons who have allergies to the test food 4.Persons who usually take a large amount of test food 5.Persons who usually take medicine, specified health food, healthy food and supplements that may affect blood pressure and salt absorption/excretion 6.Persons who have a drinking habit (drinking more than 1 go of sake per drinking day on 3 or more days a week) 7.Systolic blood pressure of 160 mmHg or more or diastolic blood pressure of 100 mmHg or more 8.BMI less than 18.5 or greater than 30 9.Persons who have participated in other tests within the first month before the start of the test, or those who intend to participate in another exam after consenting to this exam 10.Persons who were judged as inappropriate for study participants by the principal investigator

Design outcomes

Primary

MeasureTime frame
Systolic and diastolic blood pressure at 4, 8, and 12 weeks after intake

Secondary

MeasureTime frame
Physical examination (weight/BMI), blood test (general biochemistry), general urinalysis

Countries

Japan

Contacts

Public ContactTakamasa Masuda

Healthcare Systems Co., Ltd. Clinical Research Department

masudat@hc-sys.jp03-6809-2722

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026